Skip to main content

DBV Technologies S.A.

DBVT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001613780

In the last 90 days, DBV Technologies S.A. insiders filed 0 open-market purchases and 1 sale; 78 institutions reported holding it in 13F filings for Q2 2026, worth $345.7M in total; Duquesne Family Office is the only superinvestor holding it.

Other share classesDBVTF

Q2 2023 vs. Q1 2023

How the institutions holding DBV Technologies S.A. changed between Q1 2023 and Q2 2023.

All holders in Q2 2023All holders in Q1 2023

13F holders of DBVT: Q1 2023 compared with Q2 2023
MeasureQ1 2023Q2 2023Change
Holders3436+2
Shares42.2M46.0M+3.77M (+8.9%)
Value$71.3M$87.4M+$16.1M (+22.5%)

New holders (6)

Institutions that held DBV Technologies S.A. at the end of Q2 2023 but not at the end of Q1 2023.

Institutions new to DBVT in Q2 2023
InstitutionSharesValue% of portfolio
Point72 Asset Management, L.P.3,112,500$5.91M0.02%
Logos Global Management LP1,200,000$2.28M0.31%
Optiver Holding B.V.39,537$75.1K0.00%
Rhumbline Advisers28,999$55.1K0.00%
Citadel Advisors LLC28,901$54.9K0.00%
Lynx1 Capital Management LP18,265$34.7K0.02%

Sold out (4)

Institutions that held DBV Technologies S.A. at the end of Q1 2023 and filed for Q2 2023 without it.

Institutions that sold out of DBVT in Q2 2023
InstitutionShares, Q1 2023Value, Q1 2023
Old Mission Capital LLC30,597$51.7K
Tower Research Capital LLC (TRC)7,233$12.0K
Advisory Services Network, LLC1,000$1.69K
TCI Wealth Advisors, Inc.20$34